How Traceability Delivers Operational Value Across Pharma Supply Chains

Every serialized pack leaves the packaging line with a complete digital identity. Commissioning has finished. Aggregation relationships exist. Packaging records match physical product movement. Confidence often ends there.

Warehouse transfers, ownership changes, contract manufacturing, product returns, and cross-border distribution generate hundreds of additional traceability events long before medicines reach patients. Every event adds another opportunity for information to become delayed, disconnected, or incomplete. Barcode quality rarely causes operational disruption. Data continuity does.

Regulatory mandates established global serialization infrastructure. Operational performance now depends on something far less visible — whether every organization handling a product contributes complete, timely, and interoperable event data throughout distribution. Reliable traceability no longer follows packages alone, it follows information moving alongside every package.¹

Growing dependence on contract manufacturing organizations, regional distribution hubs, third-party logistics providers and multinational trading networks has raised expectations beyond regulatory readiness. Investigation teams require complete event histories. Distribution teams require inventory visibility. Quality teams require rapid product verification. Recall teams require confidence that affected units can be isolated without disrupting unaffected inventory.

When Packaging Data Leaves the Packaging Line

Packaging systems assign identity. Warehouse and enterprise systems preserve history. That distinction often determines whether traceability survives beyond manufacturing.

Commissioning, aggregation and product release complete only one phase of serialization. Immediately after release, responsibility shifts toward warehouse management systems, enterprise platforms, and downstream partners responsible for recording every subsequent event. Physical product continues moving. Digital history must move with it.

Every operational transfer creates another checkpoint:

• Warehouse receipt validates incoming inventory.
• Distribution confirms product movement.
• Ownership changes extend transaction history.
• Verification requests reconstruct previous events.

Serial numbers remain unchanged throughout those activities. Product history does not.

Reliable traceability therefore depends less on successful commissioning and more on uninterrupted information flow between connected systems. Packaging execution systems cannot maintain visibility alone once products enter broader distribution networks. From that point onward, every missing event, delayed update, or disconnected repository gradually reduces confidence in traceability, even though packaging records remain technically complete.

What Is the Hidden Cost of Broken Data Continuity?

Traceability rarely breaks because products stop moving. More often, information stops moving with them. Every trading partner generates, receives, and exchanges serialized events independently. Distribution remains uninterrupted in many cases, even when transaction histories are incomplete.

Missing events often go unnoticed until verification fails, investigations begin, or products require rapid identification during an exception.

Several operational conditions gradually weaken data continuity:

• Delayed event exchange: Transaction records arrive after physical product movement, creating temporary visibility gaps.
• Incomplete event histories: Missing commissioning, shipping, or receiving events interrupt product lineage.
• Inconsistent master data: Different product or location records prevent accurate event matching across organizations.
• Disconnected repositories: Information remains available locally but cannot be reconstructed across the broader supply network.

None of these issues changes a serialized identifier. Each one reduces confidence in the history attached to that identifier. Recognizing this challenge, regulatory frameworks have shifted attention from serialization alone toward interoperable data exchange. DSCSA requirements increasingly emphasize electronic transaction information shared among authorized trading partners, while GS1 EPCIS standards provide a common framework for exchanging event data across organizations.² Focus has gradually moved from creating identifiers to preserving reliable product histories.

Reliable traceability ultimately depends on continuity rather than volume. Every complete event strengthens confidence. Every missing event weakens it.

Why Does Packaging Hierarchy Rarely Stay the Same?

Distribution begins changing packaging configurations almost immediately after product release. Full pallets become mixed cases. Cases become customer-specific shipments. Individual saleable units eventually reach hospitals, pharmacies, and healthcare professionals. Every physical change creates a traceability checkpoint.

A typical distribution sequence moves from full pallet to case picking, then to mixed customer orders, healthcare delivery, and finally returned product.

Each transition reshapes packaging hierarchy without changing product identity. Parent-child relationships must remain intact so every serialized unit can still be connected to its original shipment history. Loss of those relationships rarely affects routine distribution. Operational pressure appears later, when quality investigations require rapid reconstruction of product movement, returns verification depends on reconnecting individual units with earlier aggregation records, and recall execution benefits from identifying affected shipping units without expanding product quarantine.

GS1 Healthcare recognizes aggregation as a critical element of pharmaceutical traceability because distribution operates through changing packaging hierarchies rather than isolated saleable units.³ Packaging configurations continue evolving across warehouses and trading partners. Product history should remain complete throughout every transition.

How Reverse Logistics Changes Every Verification Decision

Outbound distribution focuses on product movement. Returns focus on product history.

Every returned unit carries a different level of operational uncertainty. Product condition, ownership history, distribution records, and verification status all influence whether inventory can re-enter legitimate supply channels or requires further investigation.

Returns processing begins with four questions:

1. Has the product already been dispensed? Product history must confirm whether saleable return requirements remain applicable.
2. Can product identity be verified? Authentication relies on complete serialized records exchanged throughout distribution, not packaging data alone.
3. Does event history remain complete? Missing transaction records or ownership changes can delay disposition decisions and trigger additional review.
4. Should inventory return to stock? Verification outcomes determine whether the product is released, quarantined, or investigated further. 

Unlike outbound shipments, reverse logistics rarely follows a predictable path. Products may return through wholesalers, healthcare professionals, or distribution partners before reaching manufacturers. Every additional handoff increases dependence on accurate event histories.

Returned inventory tests more than product authenticity. It tests whether traceability has remained intact throughout the entire distribution journey.

Why Investigation Leaves Little Room for Missing Data

Few organizations discover weaknesses in traceability during routine distribution. Those weaknesses usually surface when products must be located quickly, verified confidently, and isolated without disrupting unaffected inventory.

Every missing event creates a consequence.

• Missing aggregation records: Affected shipping units become harder to identify, expanding investigation scope beyond necessary inventory.
• Delayed partner updates: Product movement cannot be reconstructed immediately, increasing response time across trading partners.
• Incomplete event histories: Quality teams spend more time validating distribution pathways before corrective actions can begin.
• Disconnected data repositories: Multiple systems must be reviewed before reliable product history can be established.

Effective recalls depend on preparation completed long before any product is withdrawn from distribution. Complete event histories, preserved packaging relationships, and interoperable data exchange allow investigation teams to focus on affected inventory rather than reconstructing weeks of distribution activity.

FDA guidance continues to emphasize rapid product identification and transaction visibility because response time directly influences recall effectiveness. Reliable traceability shortens investigations, limits unnecessary product quarantine and strengthens confidence in decisions made during high-pressure events.

How Serialization Data Has Found a Second Purpose

Regulatory compliance created vast repositories of serialized events, and operational teams have started using those records for a very different purpose. Instead of revisiting historical transactions manually, connected event histories now support day-to-day operational decisions: historical movement records help with inventory visibility by locating products across distribution networks and identifying where visibility begins to weaken; connected event histories simplify investigations into supply disruptions when unexpected delays, shortages, or shipment interruptions affect product availability; unusual distribution patterns become easier to identify for diversion monitoring when transaction records remain connected across authorized trading partners; and years of accumulated event data support operational planning by revealing recurring verification requests, exception trends, and distribution bottlenecks that often remain invisible in packaging systems alone.

Continued investment across pharmaceutical packaging infrastructure reflects the industry's growing emphasis on connected traceability. Glass packaging remains an important part of that transition, particularly for injectable medicines, biologics, and other high-value therapies where product integrity and unit-level identification are critical. Investment in the global glass packaging industry is projected to increase from USD 71 billion in 2026 to USD 98 billion by 2032, reinforcing broader modernization efforts that support digital traceability, product verification, and secure distribution across pharmaceutical supply networks.⁴

Serialization repositories no longer preserve history alone. They increasingly help explain what happened, where it happened, and what requires attention next.

Success Looks Different Today

Serialization programs were once judged by successful implementation. Operational maturity is measured differently.

Questions increasingly shaping traceability performance include:

• Can every product movement be reconstructed? Complete event histories should remain available across manufacturing, warehousing, distribution, and reverse logistics.
• How quickly can product history be verified? Investigation teams depend on immediate access to accurate transaction records instead of manual reconciliation.
• Can trading partners exchange information without interruption? Interoperable data exchange has become as important as barcode quality during routine operations and high-priority investigations.
• Does traceability remain intact after packaging changes? Aggregation relationships should continue supporting verification, returns processing, and targeted recalls even after products pass through multiple distribution stages.
• Are exceptions identified before they become disruptions? Reliable event histories help organizations detect missing records, delayed transactions, and visibility gaps before they affect product availability.

Mature traceability programs no longer measure success by serial number generation alone. Greater value comes from preserving complete product histories that remain accurate, accessible, and usable throughout every operational handoff.

What Is the Next Measure of Traceability?

Product identity is created in seconds on a packaging line. Product history develops across weeks of manufacturing, storage, distribution, verification, returns, and investigation. Every organization participating in that journey contributes another piece of traceability. Preserving those connections determines whether products can be verified with confidence, recalls remain targeted, investigations conclude quickly, and uninterrupted supply reaches patients.

Reliable traceability is no longer defined by successful serialization alone. It reflects how consistently information travels with every product, every shipment, and every operational handoff. When product history remains complete, connected, and accessible, traceability becomes far more than a regulatory requirement — it becomes a practical capability supporting safer, faster, and more resilient pharmaceutical supply chains.

Shammi Thakur is research director at MarkNtel Advisors.

References

1. US Food and Drug Administration. Drug Supply Chain Security Act (DSCSA). Accessed August 4, 2026. https://www.fda.gov/drugs/drug-supply-chain-integrity/drug-supply-chain-security-act-dscsa
2. US Food and Drug Administration. Drug Supply Chain Security Act Law and Policies. Accessed August 4, 2026. https://www.fda.gov/drugs/drug-supply-chain-security-act-dscsa/drug-supply-chain-security-act-law-and-policies
3. GS1 Healthcare. Healthcare Standards. GS1. Accessed August 4, 2026. https://www.gs1.org/industries/healthcare
4. Vyansa Intelligence. Glass Packaging Market Report: Forecast (2026-2032). Accessed August 4, 2026. https://www.vyansaintelligence.com/industry-report/glass-packaging-market-forecast